C

Chrysalis Clinical Research | St. George, UT

Research site

(Unclaimed)

Location

736 South 900 East Ste. 201, St. George, Utah, United States of America

Site insights

Top conditions

Top treatments

Pseudoephedrine

LY3298176

LY3502970

Orforglipron

Survodutide

Insulin icodec

Tirzepatide

Retatrutide

LY3437943

CT-388

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Active, not recruiting

Overweight

Obesity

Drug: CT-388

Drug: Placebo

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting

Obesity

Drug: Retatrutide

Drug: Tirzepatide

Locations recently updated

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting

Obesity

Drug: Placebo

Drug: survodutide

GV101 in Healthy Obese Participants

The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The pri...

Enrolling

Weight Management

Drug: GV101 placebo

Drug: GV101